619 related articles for article (PubMed ID: 35977202)
1. Association of Simulated COVID-19 Policy Responses for Social Restrictions and Lockdowns With Health-Adjusted Life-Years and Costs in Victoria, Australia.
Blakely T; Thompson J; Bablani L; Andersen P; Ait Ouakrim D; Carvalho N; Abraham P; Boujaoude MA; Katar A; Akpan E; Wilson N; Stevenson M
JAMA Health Forum; 2021 Jul; 2(7):e211749. PubMed ID: 35977202
[TBL] [Abstract][Full Text] [Related]
2. Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe.
Maul LV; Jamiolkowski D; Lapides RA; Mueller AM; Hauschild A; Garbe C; Lorigan P; Gershenwald JE; Ascierto PA; Long GV; Wang-Evers M; Scolyer RA; Saravi B; Augustin M; Navarini AA; Legge S; Németh IB; Jánosi ÁJ; Mocellin S; Feller A; Manstein D; Zink A; Maul JT; Buja A; Adhikari K; Roider E
JAMA Netw Open; 2024 Feb; 7(2):e2356479. PubMed ID: 38363565
[TBL] [Abstract][Full Text] [Related]
3. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
[TBL] [Abstract][Full Text] [Related]
4. Assessing COVID-19 pandemic policies and behaviours and their economic and educational trade-offs across US states from Jan 1, 2020, to July 31, 2022: an observational analysis.
Bollyky TJ; Castro E; Aravkin AY; Bhangdia K; Dalos J; Hulland EN; Kiernan S; Lastuka A; McHugh TA; Ostroff SM; Zheng P; Chaudhry HT; Ruggiero E; Turilli I; Adolph C; Amlag JO; Bang-Jensen B; Barber RM; Carter A; Chang C; Cogen RM; Collins JK; Dai X; Dangel WJ; Dapper C; Deen A; Eastus A; Erickson M; Fedosseeva T; Flaxman AD; Fullman N; Giles JR; Guo G; Hay SI; He J; Helak M; Huntley BM; Iannucci VC; Kinzel KE; LeGrand KE; Magistro B; Mokdad AH; Nassereldine H; Ozten Y; Pasovic M; Pigott DM; Reiner RC; Reinke G; Schumacher AE; Serieux E; Spurlock EE; Troeger CE; Vo AT; Vos T; Walcott R; Yazdani S; Murray CJL; Dieleman JL
Lancet; 2023 Apr; 401(10385):1341-1360. PubMed ID: 36966780
[TBL] [Abstract][Full Text] [Related]
5. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
COVID-19 Cumulative Infection Collaborators
Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
[TBL] [Abstract][Full Text] [Related]
6. Modelling SARS-CoV-2 disease progression in Australia and New Zealand: an account of an agent-based approach to support public health decision-making.
Thompson J; McClure R; Blakely T; Wilson N; Baker MG; Wijnands JS; De Sa TH; Nice K; Cruz C; Stevenson M
Aust N Z J Public Health; 2022 Jun; 46(3):292-303. PubMed ID: 35238437
[TBL] [Abstract][Full Text] [Related]
7. Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis.
Tan C; Luo X; Zhou Z; Zeng X; Wan X; Yi L; Liu Q
J Infect Public Health; 2023 Jun; 16(6):893-900. PubMed ID: 37062164
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
9. "Stay at Home, Protect the National Health Service, Save Lives": A cost benefit analysis of the lockdown in the United Kingdom.
Miles DK; Stedman M; Heald AH
Int J Clin Pract; 2021 Mar; 75(3):e13674. PubMed ID: 32790942
[TBL] [Abstract][Full Text] [Related]
10. Social Restrictions versus Testing Campaigns in the COVID-19 Crisis: A Predictive Model Based on the Spanish Case.
Candel FJ; Viayna E; Callejo D; Ramos R; San-Roman-Montero J; Barreiro P; Carretero MDM; Kolipiński A; Canora J; Zapatero A; Runken MC
Viruses; 2021 May; 13(5):. PubMed ID: 34063465
[TBL] [Abstract][Full Text] [Related]
11. A SARS-CoV-2 Surveillance System in Sub-Saharan Africa: Modeling Study for Persistence and Transmission to Inform Policy.
Post LA; Argaw ST; Jones C; Moss CB; Resnick D; Singh LN; Murphy RL; Achenbach CJ; White J; Issa TZ; Boctor MJ; Oehmke JF
J Med Internet Res; 2020 Nov; 22(11):e24248. PubMed ID: 33211026
[TBL] [Abstract][Full Text] [Related]
12. Estimating loss in capability wellbeing in the first year of the COVID-19 pandemic: a cross-sectional study of the general adult population in the UK, Australia and the Netherlands.
Mitchell PM; Morton RL; Hiligsmann M; Husbands S; Coast J
Eur J Health Econ; 2023 Jun; 24(4):609-619. PubMed ID: 35871692
[TBL] [Abstract][Full Text] [Related]
13. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021.
COVID-19 National Preparedness Collaborators
Lancet; 2022 Apr; 399(10334):1489-1512. PubMed ID: 35120592
[TBL] [Abstract][Full Text] [Related]
14. Health and economic costs of early and delayed suppression and the unmitigated spread of COVID-19: The case of Australia.
Kompas T; Grafton RQ; Che TN; Chu L; Camac J
PLoS One; 2021; 16(6):e0252400. PubMed ID: 34086731
[TBL] [Abstract][Full Text] [Related]
15. Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US.
Flaxman AD; Issema R; Barnabas RV; Ross JM
JAMA Netw Open; 2022 Apr; 5(4):e228632. PubMed ID: 35452104
[TBL] [Abstract][Full Text] [Related]
16. Exploratory comparison of Healthcare costs and benefits of the UK's Covid-19 response with four European countries.
Thom H; Walker J; Vickerman P; Hollingworth W
Eur J Public Health; 2021 Jul; 31(3):619-624. PubMed ID: 33693615
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 in Germany and China: mitigation versus elimination strategy.
Lu G; Razum O; Jahn A; Zhang Y; Sutton B; Sridhar D; Ariyoshi K; von Seidlein L; Müller O
Glob Health Action; 2021 Jan; 14(1):1875601. PubMed ID: 33472568
[No Abstract] [Full Text] [Related]
18. Policy stringency and mental health during the COVID-19 pandemic: a longitudinal analysis of data from 15 countries.
Aknin LB; Andretti B; Goldszmidt R; Helliwell JF; Petherick A; De Neve JE; Dunn EW; Fancourt D; Goldberg E; Jones SP; Karadag O; Karam E; Layard R; Saxena S; Thornton E; Whillans A; Zaki J
Lancet Public Health; 2022 May; 7(5):e417-e426. PubMed ID: 35461592
[TBL] [Abstract][Full Text] [Related]
19. Mental health consequences of COVID-19 suppression strategies in Victoria, Australia: a narrative review.
Jiang J; Akhlaghi H; Haywood D; Morrissey B; Parnis S
J Int Med Res; 2022 Nov; 50(11):3000605221134466. PubMed ID: 36352494
[TBL] [Abstract][Full Text] [Related]
20. Estimated health benefits, costs, and cost-effectiveness of eliminating industrial trans-fatty acids in Australia: A modelling study.
Marklund M; Zheng M; Veerman JL; Wu JHY
PLoS Med; 2020 Nov; 17(11):e1003407. PubMed ID: 33137090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
